Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
BridgeBio Pharma, Inc. terminated Equity Distribution Agreement, dated May 4, 2023 with Goldman Sachs & Co. LLC and Leerink Partners LLC (formerly known as SVB Securities LLC) (effective 2026-05-07).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Goldman Sachs & Co. LLC and Leerink Partners LLC (formerly known as SVB Securities LLC)
- Effective
- 2026-05-07
Exact text from the filing
On May 7, 2026, in connection with entering into the Agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC), to terminate that certain Equity Distribution Agreement, dated May 4, 2023, by and among the Company, Goldman Sachs and Leerink Partners, effective as of May 7, 2026.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
BridgeBio Pharma, Inc. entered into Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC valued at $500,000,000 (effective 2026-05-07).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Goldman Sachs & Co. LLC and Leerink Partners LLC
- Value
- $500,000,000
- Effective
- 2026-05-07
Exact text from the filing
On May 7, 2026, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC (“Goldman Sachs”) and Leerink Partners LLC (“Leerink Partners”, and together with Goldman Sachs, the “Sales Agents”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at its sole discretion and pursuant to a prospectus supplement, shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $500,000,000 (the “Placement Shares”), through the Sales Agents.
View on SEC.gov